Transjugular intrahepatic portosystemic shunt in the therapy of refractory ascites: single center point of view

Czech version

Authors: T. Fejfar ¹; V. Šafka ²; V. Jirkovský ¹; T. Vaňásek ¹; Š. Šembera ¹; Miroslav Lojík ³; J. Raupach ³; V. Chovanec ³; O. Renc ³; A. Michl ³; J. Žižka ³; A. Krajina ³; P. Hůlek ^1,4
Authors‘ workplace: II. interní gastroenterologická klinika LF UK a FN Hradec Králové ¹; Ústav fyziologie, LF UK Hradec Králové ²; Radiologická klinika FN Hradec Králové ³; Interní klinika LF OU, Ostrava ⁴
Published in: Gastroent Hepatol 2014; 68(2): 124-131
Category: Hepatology: Review article

Overview

Ascites and refractory ascites is one of the most severe complications of portal hypertension and is associated with high mortality. When ascites becomes refractory, liver transplantation, large volume paracentesis with albumin substitution or nonsurgical portocaval shunt creation – transjugular intrahepatic postosystemic shunt (TIPS), are the treatment options. The role of TIPS is still discussed. Temporary view on TIPS role in the therapy of refractory ascites and own experience with the treatment of 361 patients by TIPS in the last 22 years are referred to.

Key words:
portal hypertension – refractory ascites – transjugular intrahepatic – portosystemic shunt

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
1. 3. 2014

Accepted:
7. 4. 2014

Sources

1. Ginés P, Quintero E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7(1): 122–128.

2. Šafka V. Patofyziologie portální hypertenze. In: Ehrmann J, Hůlek P. Hepatologie. 1. ed. Praha: Grada Publishing 2010.

3. Garcia-Tsao G. D´Amico G. Predictive models in portal hypertension In: de Franchis R et al. Portal hypertension IV: proceedings of the fourth Baveno International Consensus Workshop. London: Blackwell Publishing 2006.

4. Guevara M, Cárdenas A, Uriz J et al. Prognosis in patients with cirrhosis and ascites. In: Gines P, Arroyo V, Rodés J et al (eds). Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment. Malden, Mass, USA: Blackwell 2005: 260–270.

5. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23(1): 164–176.

6. Salerno F, Borroni G, Moser P et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88(4): 514–519.

7. Guardiola J, Baliellas C, Xiol X et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002; 97(9): 2374–2378.

8. Moreau R, Delegue P, Pessione F et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int 2004; 24(5): 457–464.

9. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2): 464–470.

10. Fejfar T, Safka V, Hůlek P et al. MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS. Vnitr Lek 2006; 52(9): 771–776.

11. Llach J, Gines P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patiens admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94(2): 482–487.

12. Moore KP, Wong F, Gines P et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38(1): 258–266.

13. Navasa M, Rodés J. Bacterial infections in cirrhosis. Liver Int 2004; 24(4): 277–280.

14. Lata J, Fejfar T, Krechler T et al. Spontaneous bacterial peritonitis in the Czech Republic: prevalence and aetiology. Eur J Gastroenterol Hepatol 2003; 15(7): 739–743.

15. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57(4): 1651–1653. doi: 10.1002/hep.26359.

16. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49(6): 2087–2107. doi: 10.1002/hep.22853.

17. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53(3): 397–417. doi: 10.1016/j.jhep.2010.05.004.

18. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal mpairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341(6): 403–409.

19. Cárdenas A, Ginés P. Hepatorenal Syndrome: Current Concepts. In: De Francis R et al. Portal hypertension IV: proceedings of the fourth Baveno International Consensus Workshop. London: Blackwell Publishing 2006.

20. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105(1): 229–236.

21. Gines P, Guevara M, Arroyo V et al. Hepatorenal syndrome. Lancet 2003; 362(9398): 1819–1827.

22. Gluud LL, Christensen K, Christensen E et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51(2): 576–584. doi: 10.1002/hep.23286.

23. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997; 17(3): 227–232.

24. Kiafar C, Gilani N. Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 2008; 7(4): 313–320.

25. Hůlek P, Krajina A (eds). Current Practice of TIPS. Hradec Králové: Olga Štambergová 2001.

26. Lebrec D, Giuily N, Hadengue A et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25(2): 135–144.

27. Gines P, Uriz J, Calahorra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123(6): 1839–1847.

28. Boyer TD, Haskal ZJ. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51(1): 306. doi: 10.1002/hep.23383.

29. Krajina A, Hulek P, Fejfar T et al. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol 2012; 35(6): 1295–1300. doi: 10.1007/s00270-012-0493-y.

30. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59(7): 988–1000. doi: 10.1136/gut.2009.193227.

31. Rössle M, Ochs A, Gülberg V et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342(23): 1701–1707.

32. Sanyal AJ, Genning C, Reddy KR et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124(3): 634–641.

33. Salerno F, Merli M, Riggio O et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40(3): 629–635.

34. Narahara Y, Kanazawa H, Fukuda T et al. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46(1): 78–85. doi: 10.1007/s00535-010-0282-9.

35. Albillos A, Banares R, González M et al. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43(6): 990–996.

36. Deltenre P, Mathurin P, Dharancy S et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25(2): 349–356.

37. Saab S, Nieto JM, Lewis SK et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006; 4: CD004889.

38. D’Amico G, Luca A, Morabito A et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129(4): 1282–1293.

39. Salerno F, Camma C, Enea M et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133(3): 825–834.

40. Guevara M, Ginès P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28(2): 416–422.

41. Brensing KA, Textor J, Perz J et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47(2): 288–295.

42. Siegerstetter V, Deibert P, Ochs A et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001; 13(5): 529–534.

43. Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol 2002; 13(4): 385–390.

44. Wilputte JY, Goffette P, Zech F et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 2007; 70(1): 6–10.

45. Dhanasekaran R, West JK, Gonzales PC et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol 2010; 105(3): 635–641. doi: 10.1038/ajg.2009.634.